Patents by Inventor Andrew Neil Charles Weir

Andrew Neil Charles Weir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7977464
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: July 12, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: 7718157
    Abstract: Targeted lipids and lipid particles are described which are assemblies of multipolar lipids, targeting molecules such as antibodies and polyanions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: May 18, 2010
    Inventors: Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall, Michael Anthony William Eaton, Timothy John Norman, David Parker
  • Patent number: 7531676
    Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 12, 2009
    Assignee: Celltech R & D Limited
    Inventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
  • Publication number: 20080269465
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Application
    Filed: June 18, 2008
    Publication date: October 30, 2008
    Applicant: UCB PHARMA S.A.
    Inventors: DILJEET SINGH ATHWAL, DEREK THOMAS BROWN, ANDREW NEIL CHARLES WEIR, ANDREW GEORGE POPPLEWELL, ANDREW PAUL CHAPMAN, DAVID JOHN KING
  • Patent number: 7402662
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: July 22, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Dilijeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: 7186820
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: March 6, 2007
    Assignee: UCB Celltech
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: 7012135
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: March 14, 2006
    Assignee: Celltech Chiroscience Limited
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Publication number: 20040024220
    Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.
    Type: Application
    Filed: May 9, 2003
    Publication date: February 5, 2004
    Applicant: CELLTECH R & D LIMITED
    Inventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
  • Patent number: 6583301
    Abstract: Bipolar lipids are described which are able to form complexes with polyanions. The lipids comprise a cationic head linked to a hydrophobic backbone and a hydrophilic tail and are capable of self assembly to form stable complexes in aqueous solutions. The lipids are of particular use for the delivery of bioactive substances such as nucleic acids to cells in vitro and especially in vivo.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: June 24, 2003
    Assignee: Celltech R & D Limited
    Inventors: Michael Anthony William Eaton, Timothy John Norman, David Parker, Terence Seward Baker, Andrew Neil Charles Weir, Catherine Fiona Catterall
  • Publication number: 20030077249
    Abstract: A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components.
    Type: Application
    Filed: May 17, 1999
    Publication date: April 24, 2003
    Inventors: CHRISTOPHER ROBERT BEBBINGTON, ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW NEIL, CHARLES WEIR, HELENE MARGARET FINNEY
  • Publication number: 20030060444
    Abstract: A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components. At least one of the cytoplasmic signalling components is derived from all or part of a tetraspan-transmembrane protein, CD43, CD6, a mannose, U17, IL-12 or complement receptor, an integrin-associated protein, or a &ggr;-chain associated with a cytokine receptor. The activated cell may be of use in medicine for example in the treatment of diseases such as cancer.
    Type: Application
    Filed: October 24, 2002
    Publication date: March 27, 2003
    Applicant: CELLTECH THERAPEUTICS, LTD.
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Andrew Neil Charles Weir
  • Publication number: 20030026805
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.
    Type: Application
    Filed: October 18, 2001
    Publication date: February 6, 2003
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Publication number: 20020151682
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.
    Type: Application
    Filed: September 10, 2001
    Publication date: October 17, 2002
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Patent number: 6284488
    Abstract: A method for expressing recombinant molecules in bacterial hosts in a defined medium in the absence of antibiotic selection is disclosed. The method uses an expression vector comprising a regulatable promoter by which the production of foreign proteins may be controlled during the growth phase of the culture, and origin of replication maintaining medium vector copy number and a transcriptional promoter.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: September 4, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Andrew Neil Charles Weir, Andrew Mountain
  • Patent number: 5928903
    Abstract: The invention provides a method for the expression of recombinant molecules in bacterial hosts in a defined medium in the absence of antibiotic selection. The method uses an expression vector comprising a regulatable promoter by which the production of foreign proteins may be controlled during the growth phase of the culture, an origin of replication maintaining medium vector copy number and a transcriptional terminator.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: July 27, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: Andrew Neil Charles Weir, Andrew Mountain
  • Patent number: 5665866
    Abstract: This invention relates to a process for obtaining antibodies in soluble and correctly folded and assembled form. It comprises a step to raise the temperature at a time in the process selected to facilitate the subsequent isolation of soluble, correctly folded and assembled antibody, substantially free of other antibody-related material. The operating temperature may be raised at any stage in the microbial fermentation or eukaryotic cell culture, or at any stage during extraction and purification of the antibodies.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: September 9, 1997
    Assignee: Celltech Therapeutics Limited
    Inventors: Andrew Neil Charles Weir, Neil Andrew Bailey